| First Author | Lode HN | Year | 1998 |
| Journal | Cancer Res | Volume | 58 |
| Issue | 14 | Pages | 2925-8 |
| PubMed ID | 9679947 | Mgi Jnum | J:48694 |
| Mgi Id | MGI:1274878 | Citation | Lode HN, et al. (1998) Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res 58(14):2925-8 |
| abstractText | The suppression of metastases in malignant diseases is one of the major goals in targeted chemotherapy. This was achieved with an antibody drug conjugate between a novel, rationally designed enediyene antibiotic calicheamicin theta(I)1 of exceptionally high cytotoxic potency and an antiganglioside GD2 monoclonal antibody 14G2a. Effective suppression of hepatic metastases was demonstrated in a novel syngeneic model of murine neuroblastoma that simulates the situation in patients in terms of antigen heterogeneity and presence of the target antigen on normal tissues. Here, we describe the first successful use of calicheamicin theta(I)1 for targeted chemotherapy in a clinically relevant syngeneic metastasis model. |
